Ralliant Corporation (NYSE:RAL – Get Free Report) has been assigned an average rating of “Hold” from the twelve ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $50.50.
Several analysts have recently commented on the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Ralliant in a research report on Friday, February 6th. Weiss Ratings lowered Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research report on Thursday, February 5th. Vertical Research upgraded Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday, February 6th. Citigroup decreased their price target on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, Zacks Research lowered shares of Ralliant from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th.
View Our Latest Stock Report on RAL
Insider Buying and Selling at Ralliant
Institutional Trading of Ralliant
Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Ralliant by 10.7% during the 3rd quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock valued at $637,995,000 after purchasing an additional 1,415,327 shares in the last quarter. Dodge & Cox lifted its position in shares of Ralliant by 13.3% in the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after buying an additional 1,434,376 shares during the last quarter. Viking Global Investors LP bought a new stake in shares of Ralliant during the 2nd quarter worth about $257,200,000. Millennium Management LLC increased its holdings in shares of Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after acquiring an additional 3,147,660 shares during the last quarter. Finally, State Street Corp bought a new position in shares of Ralliant in the 2nd quarter valued at approximately $213,096,000.
Ralliant Stock Performance
Shares of RAL opened at $40.78 on Friday. The company has a 50-day moving average of $47.29 and a two-hundred day moving average of $46.73. The stock has a market cap of $4.56 billion and a price-to-earnings ratio of 20.81. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58. Ralliant has a one year low of $37.27 and a one year high of $57.02.
Ralliant (NYSE:RAL – Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million during the quarter, compared to analysts’ expectations of $543.04 million. The business’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.
Ralliant Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Ralliant’s dividend payout ratio is 10.20%.
Ralliant Company Profile
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Recommended Stories
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
